TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Sitryx to attend J.P. Morgan Healthcare Conference 2026 showcasing pipeline of novel small molecule candidates targeting major autoimmune indications

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Sitryx Therapeutics
Sitryx to attend J.P. Morgan Healthcare Conference 2026 showcasing pipeline of novel small molecule candidates targeting major autoimmune indications

Sitryx Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The company is advancing its lead program SYX-5219, a first-in-class oral PKM2 modulator for atopic dermatitis, with Phase 1b trials planned for Q1 2026. Additionally, SYX-1042, an itaconate mimetic, completed Phase 1 studies and is positioned to move to Phase 2 patient efficacy studies in 2026.

Insights
LLY   neutral

Eli Lilly is mentioned as a specialist investor in Sitryx's funding syndicate, indicating strategic interest in the company's immunology programs. However, this is a passive investment relationship with no direct operational involvement disclosed.